Category News

EU Approves Subcutaneous Opdivo with Halozyme’s ENHANZE for Multiple Tumors

Halozyme and Bristol Myers Squibb Secure European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE in Multiple Solid Tumors Halozyme Therapeutics celebrates a significant regulatory milestone as Bristol Myers Squibb gains European Commission approval for a new subcutaneous formulation of…

Read MoreEU Approves Subcutaneous Opdivo with Halozyme’s ENHANZE for Multiple Tumors

CHMP Recommends EU Approval of Imfinzi as First Perioperative Immunotherapy for Bladder Cancer

AstraZeneca’s Imfinzi Gains CHMP Backing as First Perioperative Immunotherapy for Muscle-Invasive Bladder Cancer in the EU AstraZeneca has announced a significant regulatory milestone for its cancer immunotherapy, Imfinzi (durvalumab), with the drug receiving a positive recommendation from the Committee for…

Read MoreCHMP Recommends EU Approval of Imfinzi as First Perioperative Immunotherapy for Bladder Cancer

Lupin and SteinCares Announce License and Supply Partnership for Ranibizumab Across Latin America

Lupin and SteinCares Forge Strategic License and Supply Agreement to Commercialize Ranibizumab Biosimilar Across Latin America Global pharmaceutical leader Lupin Limited (Lupin) has officially announced the signing of a significant license and supply agreement with SteinCares, a prominent specialty healthcare…

Read MoreLupin and SteinCares Announce License and Supply Partnership for Ranibizumab Across Latin America